Case Studies

Learn how Syngene supported leading animal health company Zoetis, manufacture the drug substance for Librela® (bedinvetmab), a first-in-class monoclonal antibody, to treat osteoarthritis in dogs.

Learn how Syngene successfully identified a first-in-class, potent, and efficacious inhibitor for the apical sodium-dependent bile acid transporter and sodium/taurocholate co-transporting polypeptide targets for treating cholestatic diseases.

Learn how Syngene transitioned a drug meant for treating erectile dysfunction from late-phase discovery to early-phase clinical studies for an emerging pharma company.

Learn how Syngene supported a global pharma company in conducting human pharmacological studies for Semglutide as an injectable while overcoming clinical and analytical challenges.

Learn how Syngene helped generate human iPSCs gene knockouts with >95% efficiency for an allogeneic cell and gene therapy.

Learn how Syngene developed a robust and scalable Green GMP manufacturing process for an oncology drug compound in just eight weeks, which reduced costs by 30%.

Learn how Syngene used its proprietary platform process for pDNA manufacturing from discovery to the clinic to deliver >90% purity pDNA.

Learn how Syngene synthesized a complex polymer using the RAFT technique and delivered several kilograms of the polymer in just one month.

Learn how Syngene successfully developed and manufactured several kilograms of a PROTAC molecule under cGMP conditions within 12 months for treating a certain type of cancer.

Learn how Syngene reduced the number of steps required to synthesize an RSM for two API candidates by 50% and successfully manufactured and supplied the GMP product to the client.